Our NGS capabilities enable the detection of low-frequency variants and rare mutations with high confidence, crucial for identifying residual disease that might be missed by less sensitive methods.
We can identify specific genetic mutations and structural changes indicative of residual cancer cells, even at very low abundance. This is particularly valuable for monitoring key mutations and expression changes in clinical phases.
RNA sequencing allows for the analysis of gene expression patterns specific to cancer cells, providing another layer of sensitivity for MRD detection and understanding disease mechanisms.
Utilizing advanced bioinformatics tools like our deep variant analysis pipeline, combined with the unparalleled read-accuracy of the Element Biosciences AVITI sequencer (>90% Q40), we achieve unprecedented accuracy in detecting rare mutations in samples.
We can develop custom enrichment kits for targeted approaches, focusing on specific regions or genes of interest with high accuracy and sensitivity to optimize MRD detection for unique project requirements.
qPCR is ideal for quickly and precisely quantifying known genetic markers associated with a patient's specific cancer, making it an excellent tool for longitudinal monitoring during and after treatment.
Biomarkers initially discovered through RNA sequencing can be translated downstream to more scalable solutions like qPCR for routine monitoring in clinical trials.
For novel or unique targets, OHMX.bio can design custom primers tailored to your specific gene or sequence of interest, ensuring highly focused and sensitive detection.
We adhere to MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines, ensuring high-quality, reproducible, and transparent qPCR results for your clinical studies.
